Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Merola

Showing results (261-270 of 442) with videos related to

Pageof 45
Sort By:
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Clinical and Experimental Dermatology|May 11, 2024
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis RegistryCarly Grant, Lourdes M Perez-Chada, Ryan W Harrison, et al.
Journal of the American Academy of Dermatology|December 16, 2020
De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysisAi-Tram N Bui, Sean Singer, Jesse Hirner, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2026
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC studyVictoria P Werth, Joseph F Merola, Richard Furie, et al.
Dermatology and Therapy|March 13, 2022
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBoni E Elewski, Andrew Blauvelt, Gaia Gallo, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology|September 17, 2019
Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disordersLourdes Perez-Chada, Vanina L Taliercio, Alice B Gottlieb, et al.
International Journal of Women'S Dermatology|May 12, 2017
Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meetingScott A Elman, Filippa Nyberg, Fukumi Furukawa, et al.
Pageof 45

Showing results (261-270 of 442) with videos related to

Sort By:
Pageof 45
Frontiers in Medicine|March 28, 2023
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetesAlexander Egeberg, Joseph F Merola, Knut Schäkel, et al.
Clinical and Experimental Dermatology|May 11, 2024
Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis RegistryCarly Grant, Lourdes M Perez-Chada, Ryan W Harrison, et al.
Journal of the American Academy of Dermatology|December 16, 2020
De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysisAi-Tram N Bui, Sean Singer, Jesse Hirner, et al.
The Journal of Rheumatology|July 15, 2023
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual MeetingMelissa P Zundell, Michael J Woodbury, Kathryn Lee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 23, 2026
Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC studyVictoria P Werth, Joseph F Merola, Richard Furie, et al.
Dermatology and Therapy|March 13, 2022
Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBoni E Elewski, Andrew Blauvelt, Gaia Gallo, et al.
Journal of the American Academy of Dermatology|June 1, 2020
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension studyAndrew Blauvelt, Kim A Papp, Joseph F Merola, et al.
The Journal of Rheumatology|July 15, 2024
Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual MeetingGretchen D Ball, Danielle Yee, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology|September 17, 2019
Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disordersLourdes Perez-Chada, Vanina L Taliercio, Alice B Gottlieb, et al.
International Journal of Women'S Dermatology|May 12, 2017
Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meetingScott A Elman, Filippa Nyberg, Fukumi Furukawa, et al.
Pageof 45